Alector has completed subject enrolment in the 76-week, randomised, Phase II PROGRESS-AD trial, which is assessing the ...

(Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating ...

Alector has announced the completion of enrollment for its Phase II clinical trial, PROGRESS-AD, evaluating the safety and ...

Alector (ALEC) announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of ...

GSK already has clinical-stage Alzheimer’s disease programs from a partnership with Alector that began 2021. Latozinemab (formerly AL001) is in Phase 3 testing; Alector has said it expects ...

GSK is hoping to use the platform to develop ... Other neuroscience-focused deals include a partnership with Alector on progranulin-elevating monoclonal antibodies for Alzheimer's and Parkinson's ...

Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology GSK plc (LSE/NYSE: GSK) is partnering with Brooke Shields, as part of its THRIVE@50+ campaign, to ...

Alector currently has two late-stage clinical ... expectations of our collaboration with GSK, expectations of our interactions with regulatory authorities, and financial and cash guidance.

Alector currently has two late-stage clinical candidates and ... expectations of our collaboration with GSK, expectations of our interactions with regulatory authorities, and financial and cash ...